An observational study in Lymphoma, Follicular, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University Hospital, Lille · Observational
This is an observational, single-center, longitudinal cohort study. In order to evaluate the gonadotoxicity of chemotherapy, an AMH monitoring was initiated in 2006 in our fertility observatory in young patients with lymphoma before, during and after chemotherapy. This study is part of the project "She will get better and then want a child" and is supported by the ARS hauts de France (n° DOS/SDES/AR/FIR/2019/282). Our first study published in 2010 shows that AMH decreases sharply during chemotherapy, regardless of the chemotherapy protocol. At the end of chemotherapy, AMH recovery profiles differ according to the protocol received. This follow-up is therefore essential in order to adapt our practices and our preservation strategies, particularly to the type of chemotherapy. Patients are primarily concerned about their chances of subsequent pregnancy, and there is little evidence in the literature about the impact of chemotherapy on ovarian reserve and long-term fertility.
The fisrt objective of our study is to evaluate, at distance from chemotherapy, the evolution of ovarian function in patients treated for lymphoma by evaluating follicular reserve parameters (AMH and antral follicle count) at 5 and 10 years after the end of chemotherapy compared with the initial workup performed before chemotherapy and the workup performed at 12 months after the end of chemotherapy.
931 studies on the registry are indexed under Lymphoma, Follicular; 237 are open to participants now.
This study's planned enrollment of 270 is above the median of 184 across 99 observational studies indexed under Lymphoma, Follicular.
Browse Lymphoma, Follicular studies →University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.
Counted across the registry records on this site, refreshed daily.
lymphoma patients treated with chemotherapy included in the fertility observatory
Exclusion Criteria:
Follicular reserve parameters (AMH and antral follicle count)
Follicular reserve parameters (AMH and antral follicle count) at 5 and 10 years after the end of chemotherapy compared with the initial workup performed before chemotherapy and the workup performed at 12 months after the end of chemotherapy
Time frame: at the end of chemotherapy
Cumulative incidence of pregnancy at 5 years and 10 years from the end of treatment defined by the achievement of at least one spontaneous or induced pregnancy.
Time frame: at 5 and 10 years after the end of chemotherapy.
Pregnancy rate obtained by ART (with or without gamete reuse)
defined by the ratio between the number of clinical pregnancies and the number of ART attempts performed (with or without gamete reuse or frozen ovarian tissue).
Time frame: at 5 and 10 years after the end of chemotherapy.
Rate of miscarriages, ectopic pregnancies, and live births (single, multiple)
defined by the ratio of the number of miscarriages, ectopic pregnancies, and live births to the number of pregnancies obtained by ART (with or without reuse of gametes or frozen ovarian tissue).
Time frame: at 5 and 10 years after the end of chemotherapy.
Scores on the Reproductive Concerns (RCACS)
Time frame: at 5 and 10 years after the end of chemotherapy.
Scores Mood (PHQ)
Time frame: at 5 and 10 years after the end of chemotherapy.
Quality of Life (FACT-G7)
Time frame: at 5 and 10 years after the end of chemotherapy.
Life Satisfaction (SWLS) scales
Time frame: at 5 and 10 years after the end of chemotherapy.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille